Literature DB >> 21286804

A non-BRCA1/2 hereditary breast cancer sub-group defined by aCGH profiling of genetically related patients.

M A Didraga1, E H van Beers, S A Joosse, K I M Brandwijk, R A Oldenburg, L F A Wessels, F B L Hogervorst, M J Ligtenberg, N Hoogerbrugge, S Verhoef, P Devilee, P M Nederlof.   

Abstract

Germline mutations in BRCA1 and BRCA2 explain approximately 25% of all familial breast cancers. Despite intense efforts to find additional high-risk breast cancer genes (BRCAx) using linkage analysis, none have been reported thus far. Here we explore the hypothesis that BRCAx breast tumors from genetically related patients share a somatic genetic etiology that might be revealed by array comparative genomic hybridization (aCGH) profiling. As BRCA1 and BRCA2 tumors can be identified on the basis of specific genomic profiles, the same may be true for a subset of BRCAx families. Analyses used aCGH to compare 58 non-BRCA1/2 familial breast tumors (designated BRCAx) to sporadic (non-familiar) controls, BRCA1 and BRCA2 tumors. The selection criteria for BRCAx families included at least three cases of breast cancer diagnosed before the age of 60 in the family, and the absence of ovarian or male breast cancer. Hierarchical cluster analysis was performed to determine sub-groups within the BRCAx tumor class and family heterogeneity. Analysis of aCGH profiles of BRCAx tumors indicated that they constitute a heterogeneous class, but are distinct from both sporadic and BRCA1/2 tumors. The BRCAx class could be divided into sub-groups. One subgroup was characterized by a gain of chromosome 22. Tumors from family members were classified within the same sub-group in agreement with the hypothesis that tumors from the same family would harbor a similar genetic background. This approach provides a method to target a sub-group of BRCAx families for further linkage analysis studies.

Entities:  

Mesh:

Year:  2011        PMID: 21286804     DOI: 10.1007/s10549-011-1357-x

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  13 in total

1.  Single-base LOH can be used as Specific Marker to Classify BRCAx Familial Breast Cancer into More Homogenous Subtypes.

Authors:  Bradley Downs; Fengxia Xiao; Yeong C Kim; Pei Xian Chen; Dali Huang; Elizabeth A Fleissner; Kenneth Cowan; San Ming Wang
Journal:  Breast J       Date:  2017-01-24       Impact factor: 2.431

Review 2.  The complex genetic landscape of familial breast cancer.

Authors:  Lorenzo Melchor; Javier Benítez
Journal:  Hum Genet       Date:  2013-04-05       Impact factor: 4.132

Review 3.  Etiology of familial breast cancer with undetected BRCA1 and BRCA2 mutations: clinical implications.

Authors:  Eugenia Yiannakopoulou
Journal:  Cell Oncol (Dordr)       Date:  2013-12-04       Impact factor: 6.730

4.  Exome sequencing of germline DNA from non-BRCA1/2 familial breast cancer cases selected on the basis of aCGH tumor profiling.

Authors:  Florentine S Hilbers; Caro M Meijers; Jeroen F J Laros; Michiel van Galen; Nicoline Hoogerbrugge; Hans F A Vasen; Petra M Nederlof; Juul T Wijnen; Christi J van Asperen; Peter Devilee
Journal:  PLoS One       Date:  2013-01-31       Impact factor: 3.240

5.  MUTYH gene variants and breast cancer in a Dutch case–control study.

Authors:  Astrid A Out; Marijke Wasielewski; Petra E A Huijts; Ivonne J H M van Minderhout; Jeanine J Houwing-Duistermaat; Carli M J Tops; Maartje Nielsen; Caroline Seynaeve; Juul T Wijnen; Martijn H Breuning; Christi J van Asperen; Mieke Schutte; Frederik J Hes; Peter Devilee
Journal:  Breast Cancer Res Treat       Date:  2012-07       Impact factor: 4.872

6.  Clinical and genetic characterization of basal cell carcinoma and breast cancer in a single patient.

Authors:  Alessandra Morelle; Rodrigo Cericatto; Ana Cristina Victorino Krepischi; Itamar Romano Garcia Ruiz
Journal:  Springerplus       Date:  2014-08-22

7.  A whole-genome massively parallel sequencing analysis of BRCA1 mutant oestrogen receptor-negative and -positive breast cancers.

Authors:  Rachael Natrajan; Alan Mackay; Maryou B Lambros; Britta Weigelt; Paul M Wilkerson; Elodie Manie; Anita Grigoriadis; Roger A'Hern; Petra van der Groep; Iwanka Kozarewa; Tatiana Popova; Odette Mariani; Samra Turaljic; Simon J Furney; Richard Marais; Daniel-Nava Rodruigues; Adriana C Flora; Patty Wai; Vidya Pawar; Simon McDade; Jason Carroll; Dominique Stoppa-Lyonnet; Andrew R Green; Ian O Ellis; Charles Swanton; Paul van Diest; Olivier Delattre; Christopher J Lord; William D Foulkes; Anne Vincent-Salomon; Alan Ashworth; Marc Henri Stern; Jorge S Reis-Filho
Journal:  J Pathol       Date:  2012-02-23       Impact factor: 7.996

8.  DNA copy number profiling reveals extensive genomic loss in hereditary BRCA1 and BRCA2 ovarian carcinomas.

Authors:  M M Kamieniak; I Muñoz-Repeto; D Rico; A Osorio; M Urioste; J García-Donas; S Hernando; L Robles-Díaz; T Ramón Y Cajal; A Cazorla; R Sáez; J M García-Bueno; S Domingo; S Borrego; J Palacios; M A van de Wiel; B Ylstra; J Benítez; M J García
Journal:  Br J Cancer       Date:  2013-04-04       Impact factor: 7.640

9.  RNA profiling reveals familial aggregation of molecular subtypes in non-BRCA1/2 breast cancer families.

Authors:  Martin J Larsen; Mads Thomassen; Qihua Tan; Anne-Vibeke Lænkholm; Martin Bak; Kristina P Sørensen; Mette Klarskov Andersen; Torben A Kruse; Anne-Marie Gerdes
Journal:  BMC Med Genomics       Date:  2014-01-31       Impact factor: 3.063

10.  Double Heterozygosity of BRCA2 and STK11 in Familial Breast Cancer Detected by Exome Sequencing.

Authors:  Mojgan Ataei-Kachouei; Javad Nadaf; Mohammad Taghi Akbari; Morteza Atri; Jacek Majewski; Yasser Riazalhosseini; Masoud Garshasbi
Journal:  Iran J Public Health       Date:  2015-10       Impact factor: 1.429

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.